Sign up here to receive news updates via email.
-
February 27, 2020 |
Media, Press Releases
BERG Files Patent Application For First In Class Small Molecule Modulators Of A Novel Target Identified By BERG’s Interrogative Biology® Platform
read moreUbiquitin Conjugating Enzyme (E2) serves as key target to BERG’s oncology therapeutics discovery efforts NEWS PROVIDED BY BERG February 27, 14:00 ET FRAMINGHAM, Mass., Feb. 27, 2020 /PRNewswire/ — BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of disease, today announced the filing of a patent application…
-
February 14, 2020 |
Media, Press Releases
BERG Presents Data Demonstrating That BPM31510 Promotes Cytotoxic T-cell Function And Influences Checkpoint Receptor Expression Patterns To Potentially Synergize Anti-Cancer Effect In Combination With I/O Therapies
read moreIn vivo and ex vivo studies of BPM31510 show its role promoting cytotoxic T-cell function and reversing indices of T-cell exhaustion and immunosuppression NEWS PROVIDED BY BERG Nov 08, 2019, 07:00 ET FRAMINGHAM, Mass., Nov. 8, 2019 /PRNewswire/ — BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of…
-
January 29, 2020 |
Media, Press Releases
BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting
read moreBERG Presents Clinical Target Validation Data for the Treatment of Parkinson’s Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018 NEWS PROVIDED BY BERG January 24, 2020 18:52 ET SHARE THIS ARTICLE FRAMINGHAM, Mass., Jan. 24, 2020 /PRNewswire/ — BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers…
-
October 22, 2019 |
Media, Press Releases
BERG Collaboration Identifies Novel Mechanism Of Action Of Redox Regulation By BPM 31510 In Models Of Glioblastoma
read moreIn vivo and in vitro studies of BPM 31510 demonstrate its effect on the survival of preclinical glioblastoma models through the induction of oxidative stress NEWS PROVIDED BY BERG October 22, 2019, 07:00 ET FRAMINGHAM, Mass., Oct. 22, 2019 /PRNewswire/ — BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of…
-
October 3, 2019 |
Media, Press Releases
BERG PRESENTS FIRST-IN-KIND DATA USING ITS BAYESIAN AI-DRIVEN INTERROGATIVE BIOLOGY® TECHNOLOGY TO MAP UNDERLYING BIOLOGY OF PATIENT RESPONSES IN ADVANCED SOLID TUMOR TRIAL OF BPM31510
read moreEarly phase study of BPM31510 demonstrates BERG’s Interrogative Biology® platform can identify the molecular basis of efficacy and adverse events, offering critical insights for drug late-stage development from analyses of longitudinal patient samples NEWS PROVIDED BY BERG September 28, 2019 Framingham, Mass., September 28, 2019 — BERG, a clinical stage biopharmaceutical company that utilizes artificial…
-
September 28, 2019 |
Media, Press Releases
BERG PRESENTS FIRST-IN-KIND DATA USING ITS BAYESIAN AI-DRIVEN INTERROGATIVE BIOLOGY® TECHNOLOGY TO MAP UNDERLYING BIOLOGY OF PATIENT RESPONSES IN ADVANCED SOLID TUMOR TRIAL OF BPM31510
read moreEarly phase study of BPM31510 demonstrates BERG’s Interrogative Biology® platform can identify the molecular basis of efficacy and adverse events, offering critical insights for drug late- stage development from analyses of longitudinal patient samples. NEWS PROVIDED BY BERG September 28, 2019 Framingham, Mass., September 28, 2019 – BERG, a clinical stage biopharmaceutical company that utilizes…
